Skip to main content

Table 1 Demographic and clinical characteristics of SLE patients

From: Detection of joint involvement in patients with systemic lupus erythematosus using musculoskeletal ultrasound and its correlation with disease activity

Variable

SLE patients

Frequency (No. = 40)

Percentage (%)

Sex

Female

34

85.0

Male

6

15.0

Age in years, Mean ± SD

30.9 ± 8.2

Disease Duration (years), Mean ± SD

5.5 ± 4.2

BMI, Mean ± SD

26.95 ± 4.534

Joint involvement

Number of tender joints, Mean ± SD

5.1 ± 4.7

Number of swollen joints, Mean ± SD

1.9 ± 2

Clinical arthritis

24

60.0

Deformity (Jaccoud arthropathy)

6

15.0

Arthritis

Asymptomatic

14

35.0

Symptomatic

26

65.0

Cutaneous manifestations

30

75.0

Raynaud’s

2

5.0

Neurological manifestations

8

20.0

Cardiac manifestations

18

45.0

Pulmonary manifestations

10

25.0

Nephritis

32

80.0

Classes of renal biopsy

Indicated but the patient refused

6 (15%)

15.0

Not indicated

18 (45%)

45.0

Class III LN

4 (10%)

10

Class IV LN

6 (15%)

15

Class V LN

6

15

ECLAM score, Mean ± SD

5.2 ± 2.5

HAQ score, Mean ± SD

0.51 ± 0.3

Medications

Pulse IV steroids

22

55.0

IV Cyclophosphamide (CYC)

18

45.0

Prednisolone (oral steroids)

40

100.0

MMF

6

15.0

AZA

10

25.0

HCQ

38

95.0

  1. BMI body mass index; HAQ health assessment questionnaire; CYC Cyclophosphamide; AZA Azathioprine; HCQ Hydroxychloroquine, MMF Mycophenolate mofetil